Publications Archive

Bicoll News 2012

Bicoll Newsletter Edition 2012: Bicoll as Partner of a € 2.7 M European-Funded EuroTransBio Program Nutraceutical Research Alliance with Naturalpha (France) New Service Platform based on Innovative Fragment Library Concept Ready to Market What to expect from Bicoll in 2012 – Extension of Bicoll_News_2012: NP Synthesis and NP Isolation on Demand PDF-Download Bicoll News 2012 …

Working in the Chinese Drug Industry

Chemical & Engineering News, 89(7), February 14, 2011 “At Bicoll Biotechnology in Shanghai’s Zhangjiang Hi-Tech Park, Managing Director Kai Lamottke is skeptical that the Chinese drug industry has openings for a sizable contingent of scientists from abroad. “The scientists with foreign experience represent, in percentage terms, a tiny minority of employees in the Chinese pharmaceutical …

The roots of innovation – Can we afford to turn away from natural product drug discovery research?

European Biopharmaceutical Review, January 2011, p.52 Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA ask if the biotech industry can afford to turn away from natural product drug discovery research. One of the most successful sources of scaffolds for the identification and development of new drugs are natural …

Bicoll News 2011

Bicoll Newsletter Edition 2011 Successful joint research project on aurora kinase inhibitors with EMBL (European Molecular Biology Laboratory) Grant from Shanghai Science Technology Committee for Bicoll Biotechnology (Shanghai) Co. Ltd. Enlargement of analytical department and medicinal chemistry team What to expect from Bicoll in 2011 – extension of drug discovery cooperations; celebration of 10 years …

GENFIT: Leader of a €2.7 M European-funded EUROTRANSBIO program

Press Release of Bicoll’s OLNORME II partner Genfit SA The OLNORME II Consortium, for which GENFIT is the leader, is focused on the development of a new class of drug candidates for the prevention and treatment of cardiometabolic diseases with an inflammatory component. LILLE, France, and CAMBRIDGE, Mass., December 20th, 2010 GENFIT (Alternext: ALGFT; ISIN:FR0004163111), …

Results of research on aurora kinase inhibitors announced

BICOLL GmbH and EMBL have announced the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases. Aurora kinases have gained a great deal of attention as possible anticancer drug targets because these serine–threonine kinases are frequently overexpressed in human tumours. For a research project on genetic …

Bicoll News 2010

Bicoll Newsletter Edition 2010 Successful preliminary results in a joint research project in drug discovery from natural products with our partner Genfit SA Modernization of our laboratory facilities with focus on medicinal chemistry New Advisory Board member for Bicoll – Dr. Michael Bogenstaetter joins the team of experts What to expect from Bicoll in 2010 …

Bicoll and Genfit renew their alliance

The Franco-German partnership dating from 2007 between Genfit and Bicoll has announced successful preliminary results from their joint research project Olnorme, which could cement the relationship between the two companies for the long term. The Olnorme project was initiated in the framework of the appeal for projects by EurotransBIO and funded with 3.2 M €. …

Medikamentenentwicklung – Naturstoffe aus China

Asien rückt immer stärker in den Blickpunkt westlicher Pharma- und Biotechnologie-Unternehmen. War es zuvor noch der Aufbau reiner Produktionsstandorte, gerät nun auch moderne Forschung und Entwicklung immer mehr in den Brennpunkt des Interesses für Outsourcing-Aktivitäten. Hierbei bieten Indien, Singapur und China unterschiedliche Kompetenzen und Schnittstellen an.